Erebagen.

erebagen logo

Rapid discovery of natural product medicines and agrochemicals.

Identifying novel bioactive compounds is hard, which makes discovering new medicines and crop protection chemicals slow and expensive. Erebagen has developed a platform that enables it to engineer soil bacteria to produce new bioactive natural products with hit-rates 20x-better than synthetic chemicals currently being used in industrial screens.

Technology & Products.

Erebagen’s Gen2NCE platform combines bioinformatics and synthetic biology techniques which overcome the two major challenges of traditional natural product discovery – rediscovery and developability. Our platform has two offerings:

  1. i) Induce production of novel compounds which can’t be found through culturing alone (“Discover”)

ii) Create modified biosynthetic pathways which deliver structural variants of these natural products. (“Diversify”)

The Market.

Recent market comparables indicate that natural product discovery is undergoing a resurgence and that significant value can be obtained through partnerships with large pharma partners who are seeking privileged access to new natural products to feed into their drug development pipelines, e.g.

  • Lodo Therapeutics partnership with Genetech ($969m, 2018)
  • WarpDrive Bio partnership with Roche ($387m, 2019)
  • Adapsyn partnership with Pfizer ($160m, 2018)

We have identified five early-adopters through ICURe who want to engage in screening partnerships using our existing compound collection and a longer list of larger partners from both the pharma and agrochemical sectors that have indicated interest in partnering as our library grows.

Business Model.

In combination, Erebagen’s platform offerings open up revenue streams from i) chemical library sales; ii) co-discovery and development partnerships with pharmaceutical and agrochemical companies.

Fundraising to date.

ICURe grant £210k.
The company is currently raising £500k.

Team.

Chairman: New Hire
CSO & Co-founder: Dr Doug Roberts
Scientific Advisor & Co-founder: Prof. Greg Challis
Business Advisors: Dr Pete Charlton, Dr Rupert Osborn

Contact: douglas.roberts@warwick.ac.uk | https://www.erebagen.com (in development)

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.